Sentence examples for dose at day from inspiring English sources

The patient had complete clinical recovery following treatment with Liposomal amphotericin B at a dose of 3 mg/kg for five days followed by a subsequent 3 mg/kg dose at day ten.

Applying the second dose at day 14 was chosen to match the AMBA therapy study.

Besides, it shows the influence of timing the second dose (second dose at day 7 vs. day 14; group E vs. group D).

One patient vomited the study drug and the replacement dose at Day 1.

The most frequently reported solicited systemic symptoms were fatigue (maximum 53.8% after a second dose at Day 21, 18 60 years stratum), muscle aches (maximum 51.7% after a second dose at Day 182, 18 60 years stratum) and headache (maximum 45.1% after a second dose at Day 21, 18 60 years stratum).

The reasons these patients did not meet the criteria were early termination (three patients, 3.1%), unevenly split daily dose (9, 9.2%), patient did not take oral dose according to dosing regimen (1, 1.0%), first intravenous dose at day 7 was not between 70 ± 2% of oral dose at day 0 (6.16.1%), and incomplete PK profile (2, 2.0%).

The drugs were administered via intraperitoneal injection as follows: control: 0.2 ml of 0.9% NaCl daily for 30 days; ACBP-L alone: 7 μg/mouse ACBP-L in 0.2 ml daily for 30 days (ACBP-L batch#2008-10); Cisplalonealone: 5 mg/kg every 4 days for total 4 doses, at day 6, 11, 16, 21, according to the manufacturer's protocol (batch# 806027CF, Qilu Medicine Ltd ,Jinan, China).

Accordingly, successful vector re-administration, measured by plasma levels of hF.IX transgene product, was achieved only in animals receiving SVP[Rapa] and in the control group of naive animals dosed at day 21 with AAV8-hF.IX vector only (Fig. 1d).

The sera used for these assays were collected on day 42 from two groups of five mice each IM immunized with 10 μg BPL-inactivated LASSARAB or FILORAB1 (two doses: at day 0 and at day 28) formulated with GLA-SE adjuvant.

Four groups of either Balb/C or Fcγ knockout Balb/C (Balb/C Fcγ−/− generously donated by Dr. Jeffrey V. Ravetch, Rockefeller University) were IM immunized with 10 μg BPL-inactivated LASSARAB or FILORAB1 (two doses: at day 0 and at day 28) formulated with GLA-SE adjuvant and sera were collected on day 0 or day 35 post-immunization.

Constant work rate cycle ergometry testing at 75% maximum work rate was conducted pre-dose at Day 1 (baseline) of each treatment period (Visits 1 and 3), and at 3 h post-dose at Week 3 of each period (Visits 2 and 4).